Highly potent broadly neutralizing antibodies are a promising option for the treatment and prevention of HIV infection. Similar to available antiretroviral drugs, however, antibodies must be administered regularly due to their limited half-life. This project therefore aims to develop effective strategies for the endogenous expression of broadly neutralizing antibodies. To achieve durable sustained production of combinations of antibody-based agents after a single administration, optimized gene vectors based on adeno-associated viruses (AAV) will be generated. The results of this project will contribute to establishing long-acting antibody-mediated strategies against infectious diseases.